Terren S. Peizer - Jul 3, 2018 Form 4 Insider Report for BIOVIE INC. (BIVI)

Role
Director, 10%+ Owner
Signature
/s/ Joanne Wendy Kim, Attorney-in-Fact
Stock symbol
BIVI
Transactions as of
Jul 3, 2018
Transactions value $
$68,685,185
Form type
4
Date filed
8/26/2022, 05:10 PM
Next filing
May 11, 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIVI Common Stock Conversion of derivative security +1.6M 1.6M Aug 13, 2018 See Footnote F1, F2, F3
transaction BIVI Common Stock Award $0 +1.6K +0.1% $0.00 1.6M Jan 2, 2019 Direct F2, F4
transaction BIVI Common Stock Award $68.7M +1.53M +95.3% $45.00* 3.13M Jun 24, 2019 See Footnote F2, F3, F5
transaction BIVI Common Stock Award +1.13M +35.97% 4.25M Sep 24, 2019 See Footnote F2, F3, F6
transaction BIVI Common Stock Award +4.42K +0.1% 4.26M Jan 2, 2020 See Footnote F3, F7
transaction BIVI Common Stock Award $0 +1.6K +0.04% $0.00 4.26M Jan 2, 2020 Direct F4
transaction BIVI Common Stock Award +5.36M +125.85% 9.62M Sep 22, 2020 See Footnote F3, F8
transaction BIVI Common Stock Options Exercise $155 +1.55M +16.11% $0.00* 11.2M Sep 22, 2020 See Footnote F3, F8
transaction BIVI Common Stock Award +8.36M +74.86% 19.5M Jun 10, 2021 See Footnote F3, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIVI Series A Convertible Preferred Stock Purchase +1.6M 1.6M Jul 3, 2018 Common Stock 1.6M See Footnote F2, F3, F10
transaction BIVI Warrants (right to buy) Purchase +1.71M 1.71M Jul 3, 2018 Common Stock 1.71M $2.25 See Footnote F2, F3, F10
transaction BIVI Series A Convertible Preferred Stock Conversion of derivative security -1.6M -100% 0 Aug 3, 2018 Common Stock 1.6M See Footnote F1, F2, F3, F10
transaction BIVI Warrants (right to buy) Disposed to Issuer -1.71M -100% 0 Jun 24, 2019 Common Stock 1.71M See Footnote F2, F3, F5
transaction BIVI 10% Convertible Debenture due 2020 Award $2M $2M Sep 24, 2019 Common Stock See Footnote F3, F6
transaction BIVI Warrants (right to buy) Award +1.25M 1.25M Sep 24, 2019 Common Stock 1.25M See Footnote F2, F3, F6, F11
transaction BIVI Warrants (right to buy) Award +300K 300K Jul 13, 2020 Common Stock 300K See Footnote F3, F6, F11
transaction BIVI 10% Convertible Debenture due 2020 Disposed to Issuer -$2M 0 Sep 22, 2020 Common Stock See Footnote F3, F6, F12
transaction BIVI Warrants (right to buy) Options Exercise -1.25M -100% 0 Sep 22, 2020 Common Stock 1.25M See Footnote F2, F3, F8, F11
transaction BIVI Warrants (right to buy) Options Exercise -300K -100% 0 Sep 22, 2020 Common Stock 300K See Footnote F3, F8, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 See Exhibit 99.1
F2 Adjusted to reflect the 125-for-1 reverse stock split effectuated by the Issuer on November 22, 2019 (the "Reverse Stock Split").
F3 Acuitas Group Holdings, LLC ("Acuitas"), is an entity beneficially owned and controlled by Terren S. Peizer.
F4 The Issuer granted 1,600 shares of common stock to the reporting person as compensation for his service on the Issuer's board of directors.
F5 Pursuant to a letter agreement with the Issuer dated June 24, 2019, Acuitas agreed to modify its existing rights under the 2018 SPA and agreed to immediately exchange the 2018 Warrants such that it effectively exercised its warrant in full pursuant to a cashless exercise thereof at an assumed then-current market price of $45 per share (adjusted to reflect the Reverse Stock Split) and, as a result, received an aggregate of 95% of the shares covered thereby.
F6 See Exhibit 99.1
F7 The Issuer paid $13,487 of accrued interest on the Debenture through the issuance of 4,422 shares of the Issuer's common stock to Acuitas.
F8 See Exhibit 99.1
F9 The Issuer issued these shares to NeurMedix, Inc. ("NeurMedix") in partial consideration for the acquisition of certain assets from NeurMedix and the assumption of certain liabilities of NeurMedix pursuant to the Asset Purchase Agreement, dated April 27, 2021, by and among the Issuer, NeurMedix, Inc. and Acuitas. In connection with the closing, NeurMedix assigned the rights to receive such shares to Acuitas.
F10 See Exhibit 99.1
F11 Exercisable at the lower of $4 (adjusted to reflect the Reverse Stock Split) or 80% of the offering price to the public in the Uplisting Offering.
F12 On September 22, 2020, the Issuer paid approximately $1.8 million to Acuitas satisfy all amounts owed on the Debenture due September 24, 2020.

Remarks:

Exhibit 99.1 - Explanation of Responses